AUSTIN, Texas, March 27 (Reuters) - A Texas judge on Tuesday
finalized a $158 million agreement to settle a lawsuit that
accused Johnson & Johnson of improperly marketing its Risperdal
anti-psychotic drug to state residents in the Medicaid program.
The action in Austin by state District Judge John Dietz
paves the way for Johnson & Johnson to pay the money to the
original plaintiff, his attorneys, the state of Texas and the
federal government. It's the largest fraud recovery ever in
Texas for Medicaid, the federal-state health insurance program
for low-income people.
"We are pleased that the settlement agreement has been
brought to a close," Teresa Mueller, a spokeswoman for J&J's
Janssen Pharmaceuticals unit, said on Tuesday. "Janssen is
committed to ethical business practices, and has policies in
place to ensure its products are only promoted for their
FDA-approved indications."
The $158 million is the same amount that Johnson & Johnson
said in January that it would pay. Since then, the parties have
quibbled over the distribution of the money, according to Allen
Jones, who raised the red flag about J&J's marketing practices
while working with the state of Pennsylvania.
Johnson & Johnson declined comment on the discussions.
"The defendants wanted to have more of a say than they did
on how the monies were allocated," Tom Melsheimer, a lawyer for
Jones, told Reuters on Tuesday.
Of the $158 million, about 31 percent will go to the federal
government, 40 percent to the state of Texas, 17 percent to
Jones and the rest (roughly 12 percent) is for attorneys' fees,
according to Tommy Jacks, a lawyer for Jones.
The settlement will fully resolve all Risperdal-related
claims in Texas, Mueller said. The agreement is specific to
Texas and does not involve other state or federal Risperdal
litigation.
The deal marked the first Risperdal settlement with any U.S.
state. It settles claims brought by Texas in 2004 involving
alleged Medicaid overpayments during the years 1994 to 2008.
Jones said on Sunday that Johnson & Johnson was trying to
reduce the amount that he received in what he characterized as
an effort to discourage whistleblowers.
Under state law, Jones was entitled to receive between 15
and 25 percent of the settlement, said Tom Kelley, a spokesman
for Texas Attorney General Greg Abbott.
Jones said on Tuesday that the 17 percent he is getting is
"far, far more" than what Johnson & Johnson wanted to pay but
that "this has never been about the bucks."
"I have done all that I can to expose Johnson & Johnson,"
Jones told Reuters on Tuesday.
Kelley said that Texas officials "are completely happy" with
the settlement and that Texas taxpayers are receiving a larger
allocation than initially planned.
(Reporting by Corrie MacLaggan)
Follow us on Twitter: @ReutersLegal